Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline Review, H1 2015

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline Review, H1 2015', provides an overview of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 10

Therapeutics Development 11

Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Overview 11

Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Comparative Analysis 12

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Therapeutics under Development by Companies 13

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Therapeutics under Investigation by Universities/Institutes 18

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Products under Development by Companies 22

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Products under Investigation by Universities/Institutes 27

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Companies Involved in Therapeutics Development 28

A. Menarini Industrie Farmaceutiche Riunite Srl 28

Adamis Pharmaceuticals Corporation 29

Aeterna Zentaris Inc. 30

Alethia Biotherapeutics Inc. 31

Amgen Inc. 32

AnGes MG, Inc. 33

Aphios Corporation 34

Armour Therapeutics Inc. 35

Arno Therapeutics, Inc. 36

Astellas Pharma Inc. 37

Astex Pharmaceuticals, Inc. 38

AstraZeneca PLC 39

Ausio Pharmaceuticals, LLC 40

Bavarian Nordic A/S 41

Bayer AG 42

Beta Pharma, Inc. 43

Bio-Cancer Treatment International Limited 44

Biscayne Pharmaceuticals, Inc. 45

Boehringer Ingelheim GmbH 46

Celldex Therapeutics, Inc. 47

Corcept Therapeutics Incorporated 48

CureTech Ltd. 49

CytoVac A/S 50

DexTech Medical AB 51

Enceladus Pharmaceuticals BV 52

Endo Pharmaceuticals Inc. 53

EndoCeutics, Inc. 54

Endocyte, Inc. 55

Errant Gene Therapeutics, LLC 56

Fujifilm Corporation 57

Genentech, Inc. 58

Glactone Pharma AB 59

GlaxoSmithKline plc 60

GTx, Inc. 61

Harbor Therapeutics, Inc. 62

Hybrigenics S.A. 63

Incuron, LLC 64

Io Therapeutics, Inc. 65

Isis Pharmaceuticals, Inc. 66

Johnson & Johnson 67

Kinex Pharmaceuticals, LLC 68

Mediolanum farmaceutici S.p.A. 69

Medivation, Inc. 70

Merck KGaA 71

NewLink Genetics Corporation 72

Novartis AG 73

Oncogenex Pharmaceuticals, Inc. 74

Orion Oyj 75

Orphagen Pharmaceuticals, Inc. 76

Oxford BioMedica plc 77

Panacela Labs, Inc. 78

Takeda Oncology 79

Tokai Pharmaceuticals, Inc. 80

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Therapeutics Assessment 81

Assessment by Monotherapy Products 81

Assessment by Target 82

Assessment by Mechanism of Action 86

Assessment by Route of Administration 89

Assessment by Molecule Type 91

Drug Profiles 93

AB-3A4-Drug Profile 93

afatinib-Drug Profile 94

AKAGU-52-Drug Profile 98

Alecsat-Drug Profile 99

alisertib-Drug Profile 101

AM-0010-Drug Profile 105

AMPI-109-Drug Profile 106

apatorsen-Drug Profile 107

APH-0701-Drug Profile 109

AT-001-Drug Profile 110

AUS-131-Drug Profile 111

AZD-3965-Drug Profile 113

AZD-8186-Drug Profile 115

BAY-1024767-Drug Profile 116

BCT-100-Drug Profile 117

BIS-1602-Drug Profile 119

BPI-5143-Drug Profile 120

buparlisib hydrochloride-Drug Profile 121

CG-1521-Drug Profile 125

CIM-1-Drug Profile 126

Dendritic Cell Therapy to Target Mucin 1 for Prostatic Adenocarcinoma-Drug Profile 127

dexamethasone acetate-Drug Profile 128

EC-1169-Drug Profile 129

EM-5854-Drug Profile 130

EN-3356-Drug Profile 131

enzalutamide-Drug Profile 133

EPI-001-Drug Profile 136

galeterone-Drug Profile 137

GEN-0101-Drug Profile 139

GPA-500-Drug Profile 141

GPA-512-Drug Profile 142

GPB-600-Drug Profile 143

GSK-2849330-Drug Profile 144

GTx-758-Drug Profile 145

GX-301-Drug Profile 147

HE-3235-Drug Profile 148

HyperAcute Vaccine for Prostate Cancer-Drug Profile 150

inecalcitol-Drug Profile 151

ipatasertib-Drug Profile 153

IRX-4204-Drug Profile 155

ISIS-EIF4ERx-Drug Profile 157

ITK-1-Drug Profile 159

JNJ-56021927-Drug Profile 161

KRM-20-Drug Profile 163

KX-01-Drug Profile 164

LFA-102-Drug Profile 166

mepacrine-Drug Profile 168

MIA-602-Drug Profile 170

mifepristone-Drug Profile 171

MSB-0010718C-Drug Profile 174

MVA-BN-PRO-Drug Profile 175

MVI-118-Drug Profile 176

ODM-201-Drug Profile 177

onalespib-Drug Profile 179

onapristone ER-Drug Profile 182

Oncolytic Virus for Oncology-Drug Profile 184

ozarelix-Drug Profile 185

pasireotide LAR-Drug Profile 187

pasotuxizumab-Drug Profile 189

Peptide for Androgen-Independent Prostate Cancer-Drug Profile 191

pidilizumab-Drug Profile 192

radium Ra 223 dichloride-Drug Profile 194

ribociclib-Drug Profile 197

rilotumumab-Drug Profile 200

sabarubicin-Drug Profile 202

Small Molecule to Inhibit 17-Beta-HSD for Castration-Resistant Prostate Cancer-Drug Profile 204

Small Molecules to Antagonize Androgen Receptor for Castration-Resistant Prostate Cancer-Drug Profile 205

Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease-Drug Profile 206

Small Molecules to Inhibit AKR1C3 for Oncology-Drug Profile 207

solitomab-Drug Profile 208

Somadex-Drug Profile 210

SR-16388-Drug Profile 211

TeloB-VAX-Drug Profile 213

TroVax-Drug Profile 214

vandetanib-Drug Profile 217

varlilumab-Drug Profile 223

VT-464-Drug Profile 225

zoptarelin doxorubicin-Drug Profile 226

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Recent Pipeline Updates 228

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects 297

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Discontinued Products 303

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Product Development Milestones 305

Featured News & Press Releases 305

Appendix 315

Methodology 315

Coverage 315

Secondary Research 315

Primary Research 315

Expert Panel Validation 315

Contact Us 315

Disclaimer 316

List of Tables

Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2015 17

Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 20

Number of Products under Development by Companies, H1 2015 (Contd..1) 21

Number of Products under Development by Companies, H1 2015 (Contd..2) 22

Number of Products under Development by Companies, H1 2015 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H1 2015 24

Comparative Analysis by Late Stage Development, H1 2015 25

Comparative Analysis by Clinical Stage Development, H1 2015 26

Comparative Analysis by Early Stage Development, H1 2015 27

Products under Development by Companies, H1 2015 28

Products under Development by Companies, H1 2015 (Contd..1) 29

Products under Development by Companies, H1 2015 (Contd..2) 30

Products under Development by Companies, H1 2015 (Contd..3) 31

Products under Development by Companies, H1 2015 (Contd..4) 32

Products under Investigation by Universities/Institutes, H1 2015 33

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 34

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 35

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Aeterna Zentaris Inc., H1 2015 36

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Alethia Biotherapeutics Inc., H1 2015 37

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Amgen Inc., H1 2015 38

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by AnGes MG, Inc., H1 2015 39

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Aphios Corporation, H1 2015 40

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Armour Therapeutics Inc., H1 2015 41

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Arno Therapeutics, Inc., H1 2015 42

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Astellas Pharma Inc., H1 2015 43

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 44

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by AstraZeneca PLC, H1 2015 45

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Ausio Pharmaceuticals, LLC, H1 2015 46

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Bavarian Nordic A/S, H1 2015 47

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Bayer AG, H1 2015 48

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Beta Pharma, Inc., H1 2015 49

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Bio-Cancer Treatment International Limited, H1 2015 50

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Biscayne Pharmaceuticals, Inc., H1 2015 51

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 52

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Celldex Therapeutics, Inc., H1 2015 53

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Corcept Therapeutics Incorporated, H1 2015 54

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by CureTech Ltd., H1 2015 55

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by CytoVac A/S, H1 2015 56

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by DexTech Medical AB, H1 2015 57

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Enceladus Pharmaceuticals BV, H1 2015 58

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Endo Pharmaceuticals Inc., H1 2015 59

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by EndoCeutics, Inc., H1 2015 60

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Endocyte, Inc., H1 2015 61

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Errant Gene Therapeutics, LLC, H1 2015 62

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Fujifilm Corporation, H1 2015 63

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Genentech, Inc., H1 2015 64

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Glactone Pharma AB, H1 2015 65

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by GlaxoSmithKline plc, H1 2015 66

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by GTx, Inc., H1 2015 67

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Harbor Therapeutics, Inc., H1 2015 68

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Hybrigenics S.A., H1 2015 69

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Incuron, LLC, H1 2015 70

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Io Therapeutics, Inc., H1 2015 71

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Isis Pharmaceuticals, Inc., H1 2015 72

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Johnson & Johnson, H1 2015 73

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Kinex Pharmaceuticals, LLC, H1 2015 74

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Mediolanum farmaceutici S.p.A., H1 2015 75

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Medivation, Inc., H1 2015 76

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Merck KGaA, H1 2015 77

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by NewLink Genetics Corporation, H1 2015 78

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Novartis AG, H1 2015 79

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2015 80

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Orion Oyj, H1 2015 81

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Orphagen Pharmaceuticals, Inc., H1 2015 82

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Oxford BioMedica plc, H1 2015 83

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Panacela Labs, Inc., H1 2015 84

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Takeda Oncology, H1 2015 85

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Tokai Pharmaceuticals, Inc., H1 2015 86

Assessment by Monotherapy Products, H1 2015 87

Number of Products by Stage and Target, H1 2015 89

Number of Products by Stage and Mechanism of Action, H1 2015 93

Number of Products by Stage and Route of Administration, H1 2015 96

Number of Products by Stage and Molecule Type, H1 2015 98

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics-Recent Pipeline Updates, H1 2015 234

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects, H1 2015 303

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects (Contd..1), H1 2015 304

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects (Contd..2), H1 2015 305

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects (Contd..3), H1 2015 306

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects (Contd..4), H1 2015 307

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects (Contd..5), H1 2015 308

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Discontinued Products, H1 2015 309

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Discontinued Products (Contd..1), H1 2015 310

List of Figures

Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2015 17

Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 19

Number of Products under Investigation by Universities/Institutes, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 26

Comparative Analysis by Early Stage Products, H1 2015 27

Assessment by Monotherapy Products, H1 2015 87

Number of Products by Top 10 Targets, H1 2015 88

Number of Products by Stage and Top 10 Targets, H1 2015 88

Number of Products by Top 10 Mechanism of Actions, H1 2015 92

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 92

Number of Products by Top 10 Routes of Administration, H1 2015 95

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 95

Number of Products by Top 10 Molecule Types, H1 2015 97

Number of Products by Stage and Top 10 Molecule Types, H1 2015 97

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

A. Menarini Industrie Farmaceutiche Riunite Srl

Adamis Pharmaceuticals Corporation

Aeterna Zentaris Inc.

Alethia Biotherapeutics Inc.

Amgen Inc.

AnGes MG, Inc.

Aphios Corporation

Armour Therapeutics Inc.

Arno Therapeutics, Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca PLC

Ausio Pharmaceuticals, LLC

Bavarian Nordic A/S

Bayer AG

Beta Pharma, Inc.

Bio-Cancer Treatment International Limited

Biscayne Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Celldex Therapeutics, Inc.

Corcept Therapeutics Incorporated

CureTech Ltd.

CytoVac A/S

DexTech Medical AB

Enceladus Pharmaceuticals BV

Endo Pharmaceuticals Inc.

EndoCeutics, Inc.

Endocyte, Inc.

Errant Gene Therapeutics, LLC

Fujifilm Corporation

Genentech, Inc.

Glactone Pharma AB

GlaxoSmithKline plc

GTx, Inc.

Harbor Therapeutics, Inc.

Hybrigenics S.A.

Incuron, LLC

Io Therapeutics, Inc.

Isis Pharmaceuticals, Inc.

Johnson & Johnson

Kinex Pharmaceuticals, LLC

Mediolanum farmaceutici S.p.A.

Medivation, Inc.

Merck KGaA

NewLink Genetics Corporation

Novartis AG

Oncogenex Pharmaceuticals, Inc.

Orion Oyj

Orphagen Pharmaceuticals, Inc.

Oxford BioMedica plc

Panacela Labs, Inc.

Takeda Oncology

Tokai Pharmaceuticals, Inc.

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Products under Development, Key Players in Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Overview, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com